The estimated Net Worth of Steven D Goldby is at least 389 千$ dollars as of 23 May 2019. Steven Goldby owns over 4,240 units of Sunesis Pharmaceuticals Inc stock worth over 389,089$ and over the last 19 years Steven sold SNSS stock worth over 0$.
Sign up
Steven Goldby SNSS stock SEC Form 4 insiders trading
Steven has made over 12 trades of the Sunesis Pharmaceuticals Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Steven exercised 4,240 units of SNSS stock worth 22,557$ on 23 May 2019.
The largest trade Steven's ever made was buying 20,000 units of Sunesis Pharmaceuticals Inc stock on 8 January 2019 worth over 224,800$. On average, Steven trades about 2,386 units every 97 days since 2005. As of 23 May 2019 Steven still owns at least 73,137 units of Sunesis Pharmaceuticals Inc stock.
You can see the complete history of Steven Goldby stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Steven Goldby's mailing address?
Steven's mailing address filed with the SEC is C/O SUNESIS PHARMACEUTICALS, INC., 341 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Sunesis Pharmaceuticals Inc
Over the last 19 years, insiders at Sunesis Pharmaceuticals Inc have traded over 89,557,714$ worth of Sunesis Pharmaceuticals Inc stock and bought 191,253,594 units worth 84,730,221$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Peter J Barris. On average, Sunesis Pharmaceuticals Inc executives and independent directors trade stock every 67 days with the average trade being worth of 14,060,191$. The most recent stock trade was executed by Tina Gullotta on 29 May 2020, trading 6,000 units of SNSS stock currently worth 1,980$.
What does Sunesis Pharmaceuticals Inc's logo look like?
Complete history of Steven Goldby stock trades at Lifecore Biomedical Inc、Sunesis Pharmaceuticals Inc
Sunesis Pharmaceuticals Inc executives and stock owners
Sunesis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Adam Craig,
Executive Vice President - Development, Chief Medical Officer -
Stephen Ketchum,
Director -
David Stump,
Independent Director -
Homer Pearce,
Independent Director -
Nicole Onetto,
Independent Director -
Matthew Fust,
Independent Director -
Steve Carchedi,
Independent Director -
H. Ward Wolff,
Director -
Tina Gullotta,
Principal Accounting Officer, Vice President - Finance -
Dayton Misfeldt,
Chief Executive Officer, Principal Financial Officer, Secretary, Director -
James Young,
Non-Executive Independent Chairman of the Board -
Eric Bjerkholt,
EVP, CFO & Corp. Secretary -
Geoffrey M. Parker,
Director -
Steven B Ketchum,
Director -
Daniel N Jr Swisher,
President and CEO -
Oncology Impact Management ...,
-
William P. Quinn,
See Remarks -
Judith A. Fox,
See Remarks -
Patrick J Kerins,
10% owner -
Ryan D Drant,
10% owner -
Forest Baskett,
10% owner -
Peter J Barris,
10% owner -
M James Barrett,
10% owner -
Equity Opportunities Fund, ...,
-
City Capital Llc Bay City C...,
-
Scott D Sandell,
10% owner -
Krishna Kittu Kolluri,
10% owner -
Helen Susan Kim,
Director -
Joseph I De Pinto,
EVP, CCO -
Biopharma Partners Iii Lpal...,
-
Equity Opportunities Fund, ...,
-
Robert Scott Mc Dowell,
Vice President, Research -
Edward Hurwitz,
Director -
Dominique Semon,
10% owner -
Biopharma Partners Iii Lpal...,
-
Iii Eugene A Trainor,
10% owner -
Charles M Linehan,
10% owner -
Equity Opportunities Fund, ...,
-
Pincus Equity Partners Lpwa...,
-
Valerie L Pierce,
Sr. VP, GC & Corp. Secretary -
Anthony B Evnin,
Director -
Steven D Goldby,
Director -
James A Wells,
Director -
Stephen P A Fodor,
Director -
Idec Incbiogen Idec Ma Inc ...,
-
Pincus Equity Partners Lpwa...,
-
Daniel C Md Adelman,
Senior VP,Drug Discovery & Dev -
Ixmayfield Ix Management Ll...,
-
Jonathan S Leff,
Director -
Daryl B Winter,
SVP,Gen Counsel/Corp Secretary -
Capital Iv, Lp Aisling Capi...,